. 2020 Aug 25;12:285–300. doi: 10.2147/JEP.S256586

Table 1.

Monoamine Uptake Inhibition, Transporter Binding Affinity, and Selectivity for Viloxazine, Atomoxetine, and Reboxetine.

	Viloxazine	Atomoxetine	Reboxetine
[³H]-NE uptake	2300^a	3.4^b	8.2^c
[³H]-5-HT uptake	>10,000^a	390^b	1070^c
[³H]-DA uptake	NC^a	1750^b	NC^c
NET binding	155^d	2^d–5^e	1.1^e–11^f
SERT binding	17,300^d	9^d–77^e	129^e–440^f
DAT binding	>100,000^d	1080^d–1451^e	>10,000^f
K_D (SERT)/K_D (NET)	111	4
K_i (SERT)/K_i (NET)		15	40–117

Notes: All values in 10⁻⁹ M. ^aK_i calculated from rat hypothalamic synaptosomes uptake assay. ^bK_i calculated from rat cerebral cortex synaptosomes uptake assay. ^cK_i calculated from rat striatal synaptosomes uptake assay. ^dK_D calculated from competition assays using [³H]-nisoxetine for hNET, [³H]-imipramine for hSERT, and [³H]-WIN35428 for hDAT. ^eK_i calculated using specific radiolabeled ligands, [³H]-nisoxetine for NET, [³H]-paroxetine for SERT, and [³H]-WIN35428 for DAT. ^fK_i calculated using specific radiolabeled ligands, [³H]-nisoxetine for NE, [³H]-citalopram for 5-HT, and [³H]-WIN35428 for DA uptake sites. Data from these studies.¹⁵^–¹⁸

Abbreviations: 5-HT, serotonin; DA, dopamine; DAT, dopamine transporter; K_D, dissociation constant; K_i, inhibition constant; NC, not calculated; NE, norepinephrine; NET, norepinephrine transporter; SERT, serotonin transporter.